Hemodialysis Clinical Trial
— PRECEDE-KOfficial title:
Hyperkalaemia Prevalence, Recurrence and Treatment in Haemodialysis: A Prospective Multi-centre Cohort Study
Verified date | July 2023 |
Source | AstraZeneca |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The objective of this study is to evaluate the prevalence and recurrence of Hyperkalaemia (HK) in Chinese HD patients and to understand the treatment pattern of HK in China.
Status | Completed |
Enrollment | 600 |
Est. completion date | July 18, 2022 |
Est. primary completion date | July 18, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Patient aged = 18 years at the time of signing the informed consent. 2. Patients with ESRD and on haemodialysis (HD) 3. The HD treatment frequency is =2 sessions per week 4. Capable of giving signed informed consent Exclusion Criteria: 1. Acute kidney injury 2. Expected to receive renal transplantation within 6 months 3. Intracranial haemorrhage or elevated intracranial pressure within one month before enrolment 4. Shock that cannot be corrected by drugs within one month before enrolment 5. Failure to establish vascular access 6. Has been receiving peritoneal dialysis 7. Not suitable for this study judged by investigators |
Country | Name | City | State |
---|---|---|---|
China | Research Site | Beijing | Beijing |
China | Research Site | Guangzhou | Guangdong |
China | Research Site | Nanchang | Jiangxi |
China | Research Site | Ningbo | Zhejiang |
China | Research Site | Shanghai | Shanghai |
China | Research Site | Shenyang | Liaoning |
China | Research Site | Shenzhen | Guangdong |
China | Research Site | Shijiazhuang | Hebei |
China | Research Site | Taihe | Hubei |
China | Research Site | Taiyuan | Shanxi |
China | Research Site | Wenzhou | Zhejiang |
China | Research Site | Yangquan | Shanxi |
Lead Sponsor | Collaborator |
---|---|
AstraZeneca |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of patients experiencing any HK at the study enrolment or during a 24-week follow-up | Proportion of patients experiencing any HK (defined as serum potassium > 5.0 mmol/L) at the study enrolment or during a 24-week follow-up | up to 24 weeks | |
Secondary | Proportion of patients experiencing HK recurrence within 1, 2, 3, 4, 5 or 6 months (if applicable) during a 24-week follow-up including enrolment assessment | Proportion of patients experiencing HK recurrence (defined as any HK event after the first HK event) within 1, 2, 3, 4, 5 or 6 months (if applicable) during a 24-week follow-up including enrolment assessment. A HK event is defined as any serum K+> 5.0 mmol/L within an interdialytic interval, which is usually two to three days. | up to 24 weeks | |
Secondary | Proportion of patients with 2, 3, 4, 5, 6 or more than 6 events of HK during a 24-week follow-up including enrolment assessment | Proportion of patients with 2, 3, 4, 5, 6 or more than 6 events of HK during a 24-week follow-up including enrolment assessment | up to 24 weeks | |
Secondary | Intradialytic potassium shift at LIDI during the first week after patient enrolment | Intradialytic potassium shift (defined as the difference between pre- and post-dialysis K+)at LIDI during the first week after patient enrolment | up to 1 week | |
Secondary | Serum K+ at LIDI and SIDI in patients receiving HD thrice a week during the first week after patient enrolment | Serum K+ at LIDI and SIDI in patients receiving HD thrice a week during the first week after patient enrolment | up to 1 week | |
Secondary | Proportion of HK patients treated with any potassium binders and specific proportion of each potassium binder respectively during the 24-week follow up period | Proportion of HK patients treated with any potassium binders including sodium polystyrene sulfonate ( calcium polystyrene sulfonate (CPS) or sodium zirconium cyclosilicate (SZC), and specific proportion of each potassium binder respectively during the 24-week follow up period | up to 24 weeks | |
Secondary | Proportion of HK events treated with any potassium binders including SPS, CPS or SZC among total number of HK events during the 24-week follow up period | Proportion of HK events treated with any potassium binders among total number of HK events during the 24-week follow up period | up to 24 weeks | |
Secondary | Mean daily dose of SPS, CPS or SZC in patients treated with any potassium binder | Mean daily dose of SPS, CPS or SZC in patients treated with any potassium binder | up to 24 weeks | |
Secondary | Duration of the treatment of SPS, CPS or SZC in patients treated with any potassium binders | Duration of the treatment of SPS, CPS or SZC in patients treated with any potassium binders | up to 24 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04892745 -
Impact of Hemodialysis on Cutaneo-muscular Electrical Impedance
|
||
Not yet recruiting |
NCT04925674 -
Study of HEC53856 in Patients With Subjects With End-Stage Renal Disease Receiving Dialysis.
|
Phase 1 | |
Active, not recruiting |
NCT03183245 -
Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis
|
Phase 3 | |
Completed |
NCT03365635 -
Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C
|
Phase 4 | |
Withdrawn |
NCT02904343 -
Evaluation of Domestic Hemodialysis Machine: A Multi-center Clinical Study
|
N/A | |
Withdrawn |
NCT01855334 -
L-Arginine and Spironolactone Trial in Dialysis-Dependent ESRD
|
Phase 4 | |
Completed |
NCT01700465 -
Estimating and Predicting Hemodynamic Changes During Hemodialysis
|
N/A | |
Recruiting |
NCT01195519 -
The Assessment of Quality of Life in Patients With Peritoneal Dialysis and Hemodialysis
|
N/A | |
Completed |
NCT00737672 -
GORE VIABAHN Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise AV Grafts in Hemodialysis
|
Phase 3 | |
Completed |
NCT00527774 -
Effect of HCV Infection on Insulin Resistance and Malnutrition-inflammation Complex Syndrome in Regular Hemodialysis Patients
|
N/A | |
Completed |
NCT00942253 -
Exercise Training in Dialysis Patients With Restless Legs Syndrome (RLS)
|
Phase 2 | |
Completed |
NCT00224081 -
DRIVE Trial (Dialysis Patients' Response to Intravenous [IV] Iron With Elevated Ferritin)
|
Phase 4 | |
Completed |
NCT00850252 -
Use of a Lifeline Graft in the A-V Shunt Model
|
Phase 1/Phase 2 | |
Completed |
NCT00776750 -
Influenza Vaccination in Hemodialysis Patients and Renal Transplant Recipients
|
Phase 4 | |
Recruiting |
NCT06351007 -
Educational Program on Dietary Adherence and Nutritional Knowledge in Chronic Kidney Disease Patients (EPAK)
|
N/A | |
Withdrawn |
NCT03664141 -
Impact of Cannabis Oil on Nutrition in Hemodialysis Patients Study (ICON-HP Study)
|
Phase 3 | |
Completed |
NCT03909698 -
Antibiotic Dosing in Patients on Intermittent Hemodialysis
|
||
Recruiting |
NCT03311321 -
Vitamin K to Slow Progression of Cardiovascular Disease Risk in Hemodialysis Patients
|
N/A | |
Recruiting |
NCT06098924 -
HD Patients' Depression and Happiness
|
||
Recruiting |
NCT03419923 -
Three Anticoagulation Strategies for Hemodialysis in Patients at Risk of Hemorrhage
|
N/A |